Streetwise Alternative - Biofuels Sponsors
Select a name to see a detailed description, expert analysis and contact information.
|"VIVE's Q4/17 revenue of $5.1M was up 108% year over year."|
|"DXD timeline to have a commercial product is much shorter than a traditional biotech company developing a new drug."|
|"R entered into an agreement with Red Eagle Exploration."|
|"GPR reported Q4/17 revenue of $17.4M versus our estimate of $15.8M."|
|"PMN is seeking to forge partnerships with big pharmas."|